SynKIR™-310
Not Specified (Oncology)
Phase 1Active
Key Facts
About Verismo Therapeutics
Verismo Therapeutics is developing a next-generation CAR T cell therapy platform, SynKIR™, which utilizes a multi-chain KIR-CAR design to overcome the limitations of traditional single-chain CARs in solid tumors. The platform, invented by founders with deep expertise in cell therapy including the inventors of Kymriah™, has shown promising preclinical efficacy and is now entering early clinical testing. The company's lead programs, SynKIR-110 and SynKIR-310, target solid tumor indications, representing a significant opportunity in a high-unmet-need area of oncology. Verismo is a private, pre-revenue company positioned at the forefront of innovating CAR T cell therapy for solid cancers.
View full company profileTherapeutic Areas
Other Not Specified (Oncology) Drugs
| Drug | Company | Phase |
|---|---|---|
| IMGS-203 | ImmunoGenesis | Pre-clinical |
| XNW28012 | Evopoint Biosciences | Phase 3 |
| Anti-TM4SF4 Antibody | Algok Bio | Preclinical |
| Oncology 1 | Actipulse Neuroscience | Pre-clinical |
| AUR112 | Aurigene Oncology | Phase 1 |
| B7H3 Antibody-Drug Conjugate | Ellipses Pharma | Clinical |
| BC3448 | BioCity Biopharma | Phase 1 |
| BC2027 | BioCity Biopharma | Phase 1 |